EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma

Yuting Peng, Tian Guan, Yi Xiao, Shugeng Lin, Jijun Wu, Yan Lin, Juping Wang, Haoyu Zeng, Changchun Ma

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04493-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yuting Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed)/Guangd…. Hauptthemen laut MEDLINE: Mucin-1, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Induced Pluripotent Stem Cells. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Joint Funds for the Innovation of Science and Technology, Fujian Province, China, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: MUC1 is frequently overexpressed in esophageal squamous cell carcinoma (ESCC), but MUC1-targeted CAR-NK cells remain unexplored in this malignancy. METHODS: MUC1 expression was assessed by IHC in 90 ESCC specimens, 47 paired adjacent normal tissues, and normal human organs. MUC1-targeted CAR-NK cells were generated from an iPSC platform. Antitumor activity was evaluated against patient-specific ESCC organoids (PSOs), primary ESCC cells, KYSE150 and KYSE140 cells using live/dead staining, CCK-8, and xCELLigence assays. In vivo efficacy was assessed in a KYSE140 xenograft model. RESULTS: MUC1 was expressed in 70% (63/90) of ESCC cases versus 14.9% (7/47) of adjacent normal tissues (P 50% and > 80% tumor cell positivity, respectively. iPSC-derived MUC1 CAR-NK cells exhibited > 95% CAR expression across iPSC, progenitor, and mature stages. Compared with controls, MUC1 CAR-NK cells elicited potent, antigen-specific cytotoxicity against MUC1-expressing ESCC PSOs, primary cells, KYSE150, and KYSE140 in vitro and significantly suppressed KYSE140 xenograft growth in vivo. CONCLUSION: iPSC-derived MUC1-targeted CAR-NK cells exert robust and specific antitumor efficacy against human ESCC, supporting clinical translation of this off-the-shelf cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucin-1Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaInduced Pluripotent Stem CellsKiller Cells, NaturalImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsMiceXenograft Model Antitumor AssaysFemaleMaleCell Line, Tumor

Stichwörter der Autor:innen

ESCC patient-specific organoidEsophageal squamous cell carcinomaPatient-specific primary ESCC cellsiPSC-derived MUC1-targeted CAR-NK

Substanzen

Mucin-1MUC1 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Radiation Oncology, Guangdong Engineering Research Center of AI-Powered Precision Cancer Diagnostics and Therapeutics (Proposed)/Guangdong Engineering Technology Research Center of AI-Powered Precision Can…
  • Guangdong Procapzoom Bioscience Inc., Guangzhou, China.
  • Department of Thoracic Oncology, Cancer Hospital of Shantou University Medical College, Guangdong, China.
  • Radiology Department, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
  • Department of Pathology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. juping0128@163.com.
  • Department of Pathophysiology, School of Basic Medical Sciences, Bengbu Medical University, Bengbu, China. juping0128@163.com.

Förderung

  • the National Natural Science Foundation of China
  • Joint Funds for the Innovation of Science and Technology, Fujian Province, China
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Peng, Y., Guan, T., Xiao, Y., Lin, S., Wu, J., Lin, Y., Wang, J., Zeng, H., & Ma, C. (2026). Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04493-x

Vancouver

Peng Y, Guan T, Xiao Y, Lin S, Wu J, Lin Y, et al. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04493-x

BibTeX
@article{Peng2026,
  author = {Peng, Yuting and Guan, Tian and Xiao, Yi and Lin, Shugeng and Wu, Jijun and Lin, Yan and Wang, Juping and Zeng, Haoyu and Ma, Changchun},
  title = {Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04493-x}
}
Kostenlos starten →